Fewer than 10% of people eligible to benefit from obesity jabs such as Wegovy are able to get them, warns the global health agency as it releases its inaugural guidance on the therapies.
With in excess of 1,000,000,000 people worldwide now obese, it is advocating for more widespread and fairer availability to these injectable treatments.
Per projections, in excess of 2,000,000,000 could be obese by 2030 if no action is taken.
"Our latest guidance recognises that excess weight is a lifelong illness that can be addressed with thorough and ongoing support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are major barriers to universal availability to the jabs that can aid individuals in losing considerable weight, says the agency.
Skinny Jab Supply Crisis
Despite the current best projected outlook, the supply of these medications would only suffice for around 100 million people – less than 10% of the global need, according to the health organization.
The advice calls on countries and companies to widen availability, by approaches including patent sharing.
Exclusive production rights on semaglutide – the primary ingredient of a leading brand – is scheduled to end in several countries in 2026.
The Way Obesity Jabs Function
These medications imitate a biological compound to delay gastric emptying, curb appetite and boost satiety so individuals eat less.
People commonly start to lose weight within a few weeks of commencing the weekly injections.
Studies points to users may see weight return a year later of discontinuing the drug, when their normal food cravings come back.
Being overweight or obese raises your chance for experiencing health problems, including diabetes, heart disease, stroke, and some cancers.
Excess weight affects individuals in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, per the health agency.
